

## **Contura terminates Bulkamid distribution rights with Ethicon**

Contura A/S (“Contura”), a wholly owned subsidiary of Speciality European Pharma Limited (“SEP”), announced on 3 May 2013 that it had terminated its exclusive distribution agreement with Ethicon Inc. (“Ethicon”) for the distribution of Bulkamid®.

Bulkamid® is Contura’s medical device for the treatment of stress urinary incontinence (“SUI”). Worldwide rights to distribute Bulkamid® were granted to Ethicon, the women’s health subsidiary of Johnson & Johnson in 2007. Following the acquisition of Contura by SEP on 30 April 2013, the company has decided that the future of Bulkamid® will be better served in the hands of its new parent company, SEP. Termination of the current agreement will take effect in August 2013 and thereafter SEP will take over responsibility for distribution of the product.

### **Commenting on the termination, Patrick Banks, Chief Executive Officer of SEP, said:**

“This termination is the logical first step following the company’s acquisition by SEP. Taking on distribution rights for Bulkamid® was one of the major drivers for SEP’s acquisition of Contura. While sales of Bulkamid® grew steadily under Ethicon, to become the leading bulking agent in Europe, we believe that growth can be further expedited. More than 90% of current stress urinary incontinence surgery involves the use of slings and tapes. With emerging safety issues for slings and tapes so prominent in the minds of patients and doctors today, particularly in the United States, we believe there is an opportunity to promote the use of Bulkamid® for first line treatment of SUI. While we do not underestimate this challenge, we believe that the existing excellent efficacy and safety data for Bulkamid® will support this use. We also intend to invest in new studies for Bulkamid to make its case even more compelling in the future.”

### **About Bulkamid®**

Bulkamid® is a homogenous hydrophilic hydrogel used in the treatment of female stress urinary incontinence. The product was granted CE approval in 2003 and is currently sold in more than 20 countries worldwide. Bulkamid® is delivered to the patient under endoscopic control using the Bulkamid® Urethral Bulking System.





CONTURA A/S  
Sydmarken 23  
2860 Søborg

Tel.: +45 81100900  
Fax: +45 81100901  
info@contura.com  
www.contura.com

VAT Registration No. 27 05 77 16

## About SEP

SEP is the parent company of a European group which specialises in the distribution and sale of healthcare products, both pharmaceuticals and medical devices, focused primarily upon the fields of urology and urogynaecology. Its lead products are:

Bulkamid<sup>®</sup>  
Aquamid<sup>®</sup>  
Mitem<sup>®</sup>  
Regurin<sup>®</sup> XL

SEP was founded in 2006 and built an experienced and accomplished management team. On 30 April 2013, SEP acquired Contura. Contura had two marketed products at the time of its acquisition by SEP, Bulkamid<sup>®</sup> and Aquamid<sup>®</sup>. It also had a number of development programmes focused upon additional uses of its hydrogel technology. SEP has established a sales and marketing infrastructure in the leading European markets, either through its own sales force or through distribution partners. SEP has offices in the UK, Denmark, Germany, France and Italy.

-ENDS-

## For further information please contact:

**SEP**  
Patrick Banks, Chief Executive Officer

**Tel: +44 (0)20 7421 7400**

